Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vincerx Pharma, Inc. VINC
$1.69
+$0.03 (1.81%)
На 18:04, 12 мая 2023
+136.69%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
35586715.00000000
-
week52high
2.74
-
week52low
0.63
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.47849800
-
EPS
-3.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 12 авг 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 08 июн 2022 г. |
| SVB Leerink | Outperform | Outperform | 07 июн 2022 г. |
| Chardan Capital | Buy | Buy | 07 июн 2022 г. |
| B. Riley Securities | Buy | Buy | 07 июн 2022 г. |
| Chardan Capital | Buy | Buy | 17 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| THOMAS TOM C | A | 10000 | 7000 | 14 дек 2022 г. |
| Hamdy Ahmed MD | A | 73760 | 35280 | 14 дек 2022 г. |
| Izumi Raquel E. | A | 68738 | 28738 | 14 дек 2022 г. |
| Seelenberger Alexander A. | A | 56000 | 56000 | 15 ноя 2022 г. |
| Izumi Raquel E. | A | 60000 | 60000 | 15 ноя 2022 г. |
| THOMAS TOM C | A | 56000 | 56000 | 15 ноя 2022 г. |
| Hamdy Ahmed MD | A | 60000 | 60000 | 15 ноя 2022 г. |
| THOMAS TOM C | A | 58000 | 58000 | 25 авг 2022 г. |
| Izumi Raquel E. | A | 60000 | 60000 | 25 авг 2022 г. |
| Hamdy Ahmed MD | A | 60000 | 60000 | 25 авг 2022 г. |
Новостная лента
Analysts Cuts Price Target On This Small Cap But Remain Bullish
Benzinga
07 июн 2022 г. в 14:19
Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse.